Skip Navigation

A Phase 3 Study of 131I-Metaiodobenzylguanidine 131I-MIBG or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma NBL

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03126916

Study #:
CMH - ANBL1531

Start Date:
Jun 21, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03126916

View Complete Trial Details & Eligibility at ClinicalTrials.gov